Synonyms: KO947
Compound class:
Synthetic organic
Comment: KO-947 is an ERK1/2 inhibitor that is in early stage clinical development as a potential treatment for advanced solid tumours with RAS/MAPK pathway mutations.
(Note: ERK1= MAPK3, ERK2= MAPK1) |
|
No information available. |
Summary of Clinical Use |
Preliminary efficacy of KO-947 is being evaluated in Phase 1 first-in-human dose escalation study NCT03051035, in patients with advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies that have BRAF, KRAS, NRAS or HRAS mutation(s). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03051035 | First-in-Human Study of KO-947 in Non-Hematological Malignancies | Phase 1 Interventional | Kura Oncology, Inc. |